Table 1.
| Anatomical tract | HDFs | HDFs | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Disorder or disease | ICPC-Ph | n | (%) | Drug group | ATC code | n | (%) | Range*** | Median |
| General | |||||||||
| Pain | A01 | 62 | (100) | Opioids | N02A | 62 | (100) | 2–15 | 9 |
| Blood | |||||||||
| Anaemia | B80-B81 | 60 | (97) | Iron preparations | B03A | 60 | (97) | 1–6 | 3 |
| Coagulation disorders | B83 | 60 | (97) | Vitamin K antagonists | B01AA | 60 | (97) | 1–3 | 2 |
| Digestive tract | |||||||||
| Ulceric disorders | D03, D84-D87 | 62 | (100) | Antacids | A02A | 62 | (100) | 1–6 | 2 |
| H2-antagonists | A02BA | 62 | (100) | 1–3 | 1 | ||||
| H+-pump inhibitors | A02 bc | 62 | (100) | 1–2 | 1 | ||||
| Nausea | D09 | 55 | (89) | H1-antagonists | N07C | 29 | (47) | 1–3 | 1 |
| 5HT3-antagonists | A04AA | 54 | (87) | 1–3 | 1 | ||||
| Diarrhoea | D11 | 62 | (100) | Intestinal adsorbents | A07B | 62 | (100) | 1–5 | 1 |
| Constipation | D12 | 62 | (100) | Laxatives | A06A | 62 | (100) | 6–16 | 12 |
| Irritable bowel syndrome | D93 | 61 | (98) | ||||||
| Chronic enteritic disorders | D94 | 61 | (98) | Anti-inflammatory agents | A07E | 61 | (98) | 1–5 | 3 |
| Eyes and ears | |||||||||
| Glaucoma | F93 | 61 | (98) | ||||||
| Vertiginous syndromes | H82 | 56 | (90) | ||||||
| Cardiovascular tract | |||||||||
| Angina pectoris, ischaemic diseases | K74-K76 | 60 | (97) | Nitrates | C01DA | 60 | (97) | 2–3 | 3 |
| Heart failure | K77 | 61 | (98) | Cardiac glycosides | C01A | 61 | (98) | 1–2 | 1 |
| Dysrhythmia | K78-K80 | 62 | (100) | ||||||
| Hypertension | K85-K86 | 62 | (100) | Diuretics | C03 | 62 | (100) | 4–15 | 9 |
| β-blockers | C07 | 62 | (100) | 2–9 | 6 | ||||
| Calcium channel blockers | C08 | 62 | (100) | 1–7 | 5 | ||||
| ACE inhibitors | C09A | 62 | (100) | 1–5 | 3 | ||||
| Angiotensin-II inhibitors | C09C | 14 | (23) | 1 | 1 | ||||
| Haemorrhoids | K96 | 54 | (87) | ||||||
| Musculoskeletal system | |||||||||
| Rheumatic pain, Arthritic disorders | L88 | 62 | (100) | NSAIDs | M01A | 62 | (100) | 2–11 | 4 |
| Central nervous system – neurological | |||||||||
| Parkinsonism | N87 | 59 | (95) | Anti-Parkinson agents | N04 | 59 | (95) | 2–12 | 10 |
| Epileptic disorders | N88 | 62 | (100) | Antiepileptic agents | N03 | 62 | (100) | 1–13 | 9 |
| Migraine | N89 | 57 | (92) | Antimigraine agents | N02C | 57 | (92) | 1–9 | 4 |
| Central nervous system – psychiatric | |||||||||
| Anxiety, insomnia | P01-P02, P06 | 61 | (98) | Benzodiazepines Barbiturates | N05BA, N05 CD N05CA | 61 10 | (98) (16) | 1–3 1 | 1 1 |
| Depressive disorders | P03, P76 | 58 | (94) | Antidepressants | N06A | 58 | (94) | 1–14 | 7 |
| Psychotic disorders | P71-P74 | 60 | (97) | Antipsychotic agents | N05A**** | 60 | (97) | 3–25 | 16 |
| Lithium preparations | N05AN | 57 | (92) | 1–2 | 1 | ||||
| Respiratory tract | |||||||||
| Emphysema, COPD, asthma | R95-R96 | 62 | (100) | β-agonists (inhalants, systemic use) Inhalation corticosteroids Inhalation parasympatholytics Cromoglycates (inhalants) | R03A, R03C | 62 | (100) | 1–7 | 3 |
| R03BA | 62 | (100) | 1–6 | 2 | |||||
| R03BB | 61 | (98) | 1–3 | 1 | |||||
| R03 bc | 57 | (92) | 1–2 | 1 | |||||
| Endocrine system and metabolism | |||||||||
| Thyroid disorders | T85-T86 | 59 | (95) | ||||||
| Diabetes mellitus | T90 | 61 | (98) | Oral hypoglycaemics | A10B | 60 | (97) | 2–6 | 4 |
| Lipid metabolism disorders | T93 | 59 | (95) | Lipid lowering agents | C10 | 59 | (95) | 1–7 | 3 |
| Urinary tract | |||||||||
| Micturition disorders | U04 | 51 | (82) | ||||||
| Reproductive system | |||||||||
| Family planning | W11-W12 | 10 | (16) | ||||||
*
Selected set of 31 indications related to cross-sectoral pharmacotherapy
**
Selected set of 33 drug groups related to cross-sectoralpharmacotherapy
***
Range of individual drug entities included within the drug group
****
ATC code ≠ N05AN.